Biomaxima Cash Flow Conversion Efficiency

Latest as of September 2025: 0.022x

Biomaxima cash flow conversion efficiency. Based on the latest financial reports, Biomaxima (BMX) has a cash flow conversion efficiency ratio of 0.022x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (zł1.01 Million ≈ $278.79K USD) by net assets (zł46.81 Million ≈ $12.88 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Biomaxima (2009–2024)

Cash flow conversion efficiency of Biomaxima from 2009 to 2024. This chart illustrates how Biomaxima's cash flow conversion efficiency has evolved over time, based on yearly financial data. View BMX share price today for real-time trading data and today's change.

Biomaxima Cash Flow Conversion Ratio Explained

Biomaxima cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Biomaxima Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Biomaxima ranked by their cash flow conversion efficiency. Also see Biomaxima market cap and net worth for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
Seamless Distribution Systems AB ST:SDS	-0.126x
Nagambie Resources Ltd AU:NAG	-0.036x
General Engineering Public Company Limited BK:GEL	0.044x
Wetouch Technology Inc. Common Stock NASDAQ:WETH	0.004x
Agillic A/S CO:AGILC	-0.049x
OYAK Yatirim Ortakligi AS IS:OYAYO	-0.012x
MODERN COMMERCE SA ZY-10 F:8F4	-0.261x
Esthetics International Group KLSE:5081	0.079x

Annual Cash Flow Conversion Efficiency for Biomaxima (2009–2024)

The table below shows the annual cash flow conversion efficiency of Biomaxima from 2009 to 2024. Review BMX free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	zł47.33 Million ≈ $13.02 Million	zł-152.00K ≈ $-41.83K	-0.003x	-109.48%
2023-12-31	zł46.97 Million ≈ $12.93 Million	zł1.59 Million ≈ $438.14K	0.034x	-95.20%
2022-12-31	zł52.46 Million ≈ $14.44 Million	zł37.06 Million ≈ $10.20 Million	0.707x	+15726.93%
2021-12-31	zł29.19 Million ≈ $8.03 Million	zł-132.00K ≈ $-36.33K	-0.005x	-102.95%
2020-12-31	zł25.94 Million ≈ $7.14 Million	zł3.97 Million ≈ $1.09 Million	0.153x	-48.86%
2019-12-31	zł16.46 Million ≈ $4.53 Million	zł4.93 Million ≈ $1.36 Million	0.299x	+137.97%
2018-12-31	zł16.85 Million ≈ $4.64 Million	zł2.12 Million ≈ $583.53K	0.126x	+18.86%
2017-12-31	zł17.37 Million ≈ $4.78 Million	zł1.84 Million ≈ $506.23K	0.106x	+23.83%
2016-12-31	zł16.83 Million ≈ $4.63 Million	zł1.44 Million ≈ $396.07K	0.085x	-41.53%
2015-12-31	zł15.64 Million ≈ $4.30 Million	zł2.29 Million ≈ $629.38K	0.146x	+277.64%
2014-12-31	zł14.49 Million ≈ $3.99 Million	zł561.02K ≈ $154.40K	0.039x	-55.45%
2013-12-31	zł14.37 Million ≈ $3.96 Million	zł1.25 Million ≈ $343.86K	0.087x	+118.87%
2012-12-31	zł12.84 Million ≈ $3.53 Million	zł-5.91 Million ≈ $-1.63 Million	-0.460x	-297.21%
2011-12-31	zł7.85 Million ≈ $2.16 Million	zł1.83 Million ≈ $504.32K	0.234x	+1427.93%
2010-12-31	zł6.73 Million ≈ $1.85 Million	zł102.89K ≈ $28.32K	0.015x	-88.33%
2009-12-31	zł3.20 Million ≈ $879.33K	zł418.32K ≈ $115.13K	0.131x	--

About Biomaxima

WAR:BMX Poland Diagnostics & Research

Market Cap

$10.73 Million

zł39.00 Million PLN

Market Cap Rank

#26750 Global

#287 in Poland

Share Price

zł9.30

Change (1 day)

-1.80%

52-Week Range

zł9.30 - zł13.15

All Time High

zł55.45